MX376164B - Composiciones y metodos para tratar el insomnio. - Google Patents

Composiciones y metodos para tratar el insomnio.

Info

Publication number
MX376164B
MX376164B MX2017004950A MX2017004950A MX376164B MX 376164 B MX376164 B MX 376164B MX 2017004950 A MX2017004950 A MX 2017004950A MX 2017004950 A MX2017004950 A MX 2017004950A MX 376164 B MX376164 B MX 376164B
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating insomnia
insomnia
dimethylpyrimidin
Prior art date
Application number
MX2017004950A
Other languages
English (en)
Spanish (es)
Other versions
MX2017004950A (es
Inventor
Gina PASTINO
Margaret Moline
Nobuo Yoshida
Nobuya Suzuki
Yasuhiro Zaima
Yurie AKIMOTO
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2017004950A publication Critical patent/MX2017004950A/es
Publication of MX376164B publication Critical patent/MX376164B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
MX2017004950A 2014-10-23 2015-10-21 Composiciones y metodos para tratar el insomnio. MX376164B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067443P 2014-10-23 2014-10-23
PCT/JP2015/080304 WO2016063995A1 (en) 2014-10-23 2015-10-21 Compositions and methods for treating insomnia

Publications (2)

Publication Number Publication Date
MX2017004950A MX2017004950A (es) 2018-01-16
MX376164B true MX376164B (es) 2025-03-07

Family

ID=55761025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004950A MX376164B (es) 2014-10-23 2015-10-21 Composiciones y metodos para tratar el insomnio.

Country Status (14)

Country Link
US (3) US10188652B2 (enExample)
EP (1) EP3209298B1 (enExample)
JP (1) JP6659681B2 (enExample)
KR (1) KR102444608B1 (enExample)
CN (1) CN107810006B (enExample)
AU (1) AU2015336463B2 (enExample)
BR (1) BR112017007063A2 (enExample)
CA (1) CA2964504C (enExample)
ES (1) ES2843952T3 (enExample)
IL (1) IL251759B (enExample)
MX (1) MX376164B (enExample)
RU (1) RU2703297C2 (enExample)
SG (2) SG10202007759RA (enExample)
WO (1) WO2016063995A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107810006B (zh) 2014-10-23 2021-03-30 卫材R&D管理有限公司 用于治疗失眠的组合物
EP3454859B1 (en) * 2016-05-12 2021-12-01 Eisai R&D Management Co., Ltd. Methods of treating circadian rhythm sleep disorders
TWI855386B (zh) 2016-08-10 2024-09-11 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
CN110799501B (zh) 2017-08-01 2022-11-22 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
CA3119728A1 (en) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US20220305012A1 (en) * 2019-06-26 2022-09-29 Eisai R&D Management Co., Ltd. Lemborexant for treating sleep issues
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
AU2020347078A1 (en) * 2019-09-13 2022-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating insomnia
AU2020346456A1 (en) * 2019-09-13 2022-04-14 Takeda Pharmaceutical Company Limited TAK-925 for use in treating narcolepsy
US20230051268A1 (en) * 2019-12-20 2023-02-16 Eisai R&D Management Co., Ltd. Use of lemborexant for treating insomnia
JPWO2021145373A1 (enExample) * 2020-01-16 2021-07-22
PH12022552763A1 (en) * 2020-04-19 2024-03-25 Idorsia Pharmaceuticals Ltd Medical use of daridorexant
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
TW202425995A (zh) 2022-09-23 2024-07-01 日商衛材R&D企管股份有限公司 減少與神經退化疾病相關的神經退化的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
BRPI0508263B8 (pt) 2004-03-01 2021-05-25 Idorsia Pharmaceuticals Ltd derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
JP2008513434A (ja) 2004-09-23 2008-05-01 ファイザー・プロダクツ・インク トロンボポイエチン受容体アゴニスト
JP2006328057A (ja) 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
CN101400348A (zh) 2006-03-15 2009-04-01 埃科特莱茵药品有限公司 用于提高记忆功能的四氢异喹啉衍生物
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
KR20090064447A (ko) 2006-09-11 2009-06-18 글락소 그룹 리미티드 모노아민 재흡수 억제제로서의 아자바이시클릭 화합물
CL2007002809A1 (es) 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
EP2203415B1 (de) 2007-09-21 2016-10-26 Sanofi (cyclopropyl-phenyl)-phenyl-oxalamide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
JP5735010B2 (ja) * 2010-02-15 2015-06-17 コーニンクレッカ フィリップス エヌ ヴェ 制御チャネル干渉の軽減
AR083060A1 (es) * 2010-09-22 2013-01-30 Eisai R&D Man Co Ltd Compuesto de ciclopropano y composiciones farmaceuticas que lo contienen
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
CN107810006B (zh) 2014-10-23 2021-03-30 卫材R&D管理有限公司 用于治疗失眠的组合物

Also Published As

Publication number Publication date
JP2017531683A (ja) 2017-10-26
IL251759A0 (en) 2017-06-29
EP3209298B1 (en) 2020-12-02
AU2015336463B2 (en) 2020-06-18
CN107810006B (zh) 2021-03-30
AU2015336463A1 (en) 2017-05-04
MX2017004950A (es) 2018-01-16
EP3209298A1 (en) 2017-08-30
KR102444608B1 (ko) 2022-09-20
RU2017112308A (ru) 2018-11-26
CA2964504A1 (en) 2016-04-28
KR20170068478A (ko) 2017-06-19
US10702529B2 (en) 2020-07-07
BR112017007063A2 (pt) 2018-02-14
RU2017112308A3 (enExample) 2019-05-08
US20170252342A1 (en) 2017-09-07
CA2964504C (en) 2022-08-23
SG10202007759RA (en) 2020-09-29
CN107810006A (zh) 2018-03-16
WO2016063995A1 (en) 2016-04-28
IL251759B (en) 2021-01-31
US20190201399A1 (en) 2019-07-04
US10188652B2 (en) 2019-01-29
RU2703297C2 (ru) 2019-10-16
SG11201703064WA (en) 2017-05-30
US11026944B2 (en) 2021-06-08
EP3209298A4 (en) 2018-06-20
US20200268754A1 (en) 2020-08-27
JP6659681B2 (ja) 2020-03-04
ES2843952T3 (es) 2021-07-21

Similar Documents

Publication Publication Date Title
MX376164B (es) Composiciones y metodos para tratar el insomnio.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX2018006223A (es) Moduladores de ror-gamma.
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MX381640B (es) Metodos y compuestos agonistas de gip.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
MX389242B (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2015012741A (es) Palbociclib deuterado.
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
CL2015002897A1 (es) Inhibidores de bace1
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
MX2016008968A (es) Compuestos organicos.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.

Legal Events

Date Code Title Description
FG Grant or registration